4.5 Article

Fracture prediction and calibration of a Canadian FRAXA® tool: a population-based report from CaMos

Journal

OSTEOPOROSIS INTERNATIONAL
Volume 22, Issue 3, Pages 829-837

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s00198-010-1465-1

Keywords

Canada; Fracture; Fracture prediction; FRAX; Osteoporosis

Funding

  1. Merck Frosst Canada Ltd.
  2. Eli Lilly Canada Inc.
  3. Novartis Pharmaceuticals Inc.
  4. sanofi-aventis & Procter and Gamble Pharmaceuticals Canada Inc
  5. Servier Canada Inc.
  6. Amgen Canada Inc.
  7. Dairy Farmers of Canada
  8. Arthritis Society
  9. Canadian Institutes of Health Research (CIHR)

Ask authors/readers for more resources

A new Canadian WHO fracture risk assessment (FRAXA (R)) tool to predict 10-year fracture probability was compared with observed 10-year fracture outcomes in a large Canadian population-based study (CaMos). The Canadian FRAX tool showed good calibration and discrimination for both hip and major osteoporotic fractures. The purpose of this study was to validate a new Canadian WHO fracture risk assessment (FRAXA (R)) tool in a prospective, population-based cohort, the Canadian Multicentre Osteoporosis Study (CaMos). A FRAX tool calibrated to the Canadian population was developed by the WHO Collaborating Centre for Metabolic Bone Diseases using national hip fracture and mortality data. Ten-year FRAX probabilities with and without bone mineral density (BMD) were derived for CaMos women (N = 4,778) and men (N = 1,919) and compared with observed fracture outcomes to 10 years (Kaplan-Meier method). Cox proportional hazard models were used to investigate the contribution of individual FRAX variables. Mean overall 10-year FRAX probability with BMD for major osteoporotic fractures was not significantly different from the observed value in men [predicted 5.4% vs. observed 6.4% (95%CI 5.2-7.5%)] and only slightly lower in women [predicted 10.8% vs. observed 12.0% (95%CI 11.0-12.9%)]. FRAX was well calibrated for hip fracture assessment in women [predicted 2.7% vs. observed 2.7% (95%CI 2.2-3.2%)] but underestimated risk in men [predicted 1.3% vs. observed 2.4% (95%CI 1.7-3.1%)]. FRAX with BMD showed better fracture discrimination than FRAX without BMD or BMD alone. Age, body mass index, prior fragility fracture and femoral neck BMD were significant independent predictors of major osteoporotic fractures; sex, age, prior fragility fracture and femoral neck BMD were significant independent predictors of hip fractures. The Canadian FRAX tool provides predictions consistent with observed fracture rates in Canadian women and men, thereby providing a valuable tool for Canadian clinicians assessing patients at risk of fracture.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available